药物预防与治疗ICU获得性衰弱的Meta分析
该Meta分析纳入11项随机对照试验,干预组1865例、对照组1894例,评估药物预防与治疗ICU获得性衰弱(ICU-AW)的效果。质量评价显示4项A级、7项B级,总体质量较高。Meta分析显示强化胰岛素治疗可预防ICU-AW(RR=0.761,95%CI 0.662-0.876,P=0.000),但增加低血糖风险,并减少苯丙氨酸丢失和谷氨酰胺摄入。其他药物(生长激素、谷氨酰胺、右美托咪定、新斯的明、氧雄龙、静脉免疫球蛋白)与对照组相比无显著差异。结论认为无药物被推荐用于防治ICU-AW。
要点
- 强化胰岛素治疗可预防ICU-AW(RR=0.761,95%CI 0.662-0.876,P=0.000),但低血糖风险增加。
- 强化胰岛素治疗组苯丙氨酸丢失为-3±3 nmol×100 mL-1×min-1 vs 对照组-11±3 nmol×100 mL-1×min-1,P<0.05。
- 强化胰岛素治疗组谷氨酰胺摄入为-97±22 nmol×100 mL-1×min-1 vs 对照组-51±13 nmol×100 mL-1×min-1,P<0.05。
- 生长激素、谷氨酰胺、右美托咪定、新斯的明、氧雄龙、静脉免疫球蛋白在防治ICU-AW方面与对照组无显著差异。
- 结论认为目前无药物被推荐用于预防和治疗ICU-AW。
适用人群与场景
- 纳入关于药物预防与治疗ICU-AW的随机对照试验,干预组1865例、对照组1894例。
处置流程与药物剂量
- 强化胰岛素治疗可预防ICU-AW(RR=0.761,95%CI 0.662-0.876,P=0.000),但低血糖风险增加。
研究设计与关键结果
- 共纳入11项随机对照试验,干预组1865例、对照组1894例;质量评价4项A级、7项B级,总体质量较高。
- 强化胰岛素治疗可预防ICU-AW(RR=0.761,95%CI 0.662-0.876,P=0.000),但低血糖风险增加。
- 强化胰岛素治疗组苯丙氨酸丢失-3±3 nmol×100 mL-1×min-1 vs 对照组-11±3 nmol×100 mL-1×min-1,P<0.05。
- 强化胰岛素治疗组谷氨酰胺摄入-97±22 nmol×100 mL-1×min-1 vs 对照组-51±13 nmol×100 mL-1×min-1,P<0.05。
- 生长激素、谷氨酰胺、右美托咪定、新斯的明、氧雄龙、静脉免疫球蛋白在防治ICU-AW方面与对照组无显著差异。
证据类型、等级与局限
- 证据类型:系统评价/Meta分析,纳入11项随机对照试验。
- 质量评价:4项A级、7项B级,总体质量较高。
- 局限:原文未报告局限性。
对床旁实践的改变
- 强化胰岛素治疗可预防ICU-AW,但低血糖风险增加,需权衡获益与低血糖风险。
- 生长激素、谷氨酰胺、右美托咪定、新斯的明、氧雄龙、静脉免疫球蛋白在防治ICU-AW方面无显著优势,目前无药物被推荐用于防治ICU-AW。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effect of preventing and treatment of pharmaceuticals on intensive care unit-acquired weakness (ICU-AW) by systematic review.
METHODS: The randomized controlled trials (RCTs) concerning pharmaceutical prevention and treatment about ICU-AW in SinoMed, CNKI, Wanfang data, PubMed, Cochrane Library, Web of Science, EMbase, and other sources were searched from their foundation to May 30th, 2019. The patients in the intervention group were treated with drugs to prevent or treat ICU-AW; and those in control group were treated with other rehabilitation methods. Data searching, extracting and quality evaluation were assessed by two reviewers independently. Stata 12.0 software was then used for Meta-analysis. Only descriptive analysis was conducted when only one study was enrolled.
RESULTS: A total of 11 RCTs were enrolled with 1 865 patients in the intervention group and 1 894 in the control group. The results of quality evaluation showed that 4 studies were A-level and 7 studies were B-level, indicating that the overall quality of the enrolled literature was high. Meta-analysis showed that intensive insulin therapy could prevent ICU-AW [relative risk (RR) = 0.761, 95% confidence interval (95%CI) was 0.662-0.876, P = 0.000], but reduced phenylalanine loss (nmol×100 mL-1×min-1: -3±3 vs. -11±3, P < 0.05) and glutamine intake (nmol×100 mL-1×min-1: -97±22 vs. -51±13, P < 0.05). There was no significant difference in the prevention and treatment of ICU-AW between other drugs (including growth hormone, glutamine, dexmedetomidine, neostigmine, oxandrolone, and intravenous immunoglobulin) and control group.
CONCLUSIONS: Intensive insulin therapy can prevent ICU-AW, but the risk of hypoglycemia will increase. Other drugs including growth hormone, glutamine, dexmedetomidine, neostigmine, oxandrolone, and intravenous immunoglobulin have no obvious advantages in the prevention and treatment of ICU-AW, so no drug has been recommended to prevent and treat ICU-AW.
参考来源
- Yang L, Zhang Z, Zhang C, et al. [Evaluation of pharmaceutical prevention and treatment of intensive care unit-acquired weakness: a Meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32386003. doi:10.3760/cma.j.cn121430-20190821-00074
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。